SCHEMBL969649

SCHEMBL969649

CCCCNC(=O)NCC

nearest known ligand 0.74

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 8/20 0.74
EPHX2 P34913 4/20 0.50
MMP2 P08253 2/20 0.50
ACHE P22303 2/20 0.50
MMP1 P03956 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1753987 0.93 EPHX1 (0.82) EPHX1EPHX2
SCHEMBL320112 0.92 EPHX1 (0.85) EPHX1MMP2ACHEMMP1
SCHEMBL6290324 0.91 EPHX1 (0.69) EPHX1EPHX2
SCHEMBL6290512 0.91 EPHX1 (0.63) EPHX1EPHX2MMP2ACHEMMP1
SCHEMBL25270954 0.91 EPHX1 (0.86) EPHX1EPHX2
SCHEMBL8392636 0.91 EPHX1 (0.86) EPHX1EPHX2
SCHEMBL8391736 0.91 EPHX1 (0.86) EPHX1EPHX2
SCHEMBL25274521 0.91 EPHX1 (0.86) EPHX1EPHX2
SCHEMBL11236288 0.91 EPHX1 (0.86) EPHX1EPHX2
SCHEMBL8392235 0.91 EPHX1 (0.86) EPHX1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4270257-A None JP disclosed
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
CN-118382612-A Method for producing blocked isocyanate compound and method for producing isocyanate compound 旭化成株式会社 2024-07-23 CN disclosed
CN-110546566-B Positive photosensitive siloxane composition and cured film formed using same 默克专利有限公司 2024-02-09 CN disclosed
US-11860537-B2 Positive type photosensitive siloxane composition and cured film formed by using the same MERCK PATENT GMBH (DE) 2024-01-02 US disclosed
US-20230322785-A1 ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY MERCK SHARP & DOHME LLC (US) 2023-10-12 US disclosed
WO-2023106377-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND 旭化成株式会社 2023-06-15 WO disclosed
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-18 US disclosed
US-20210116811-A1 POSITIVE TYPE PHOTOSENSITIVE SILOXANE COMPOSITION AND CURED FILM FORMED BY USING THE SAME MERCK PATENT GMBH (DE) 2021-04-22 US disclosed
WO-2021061823-A1 CHEMICAL COMPOUNDS Boragen, Inc. (US) 2021-04-01 WO disclosed
US-5459147-A Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma DR. KARL THOMAE GMBH (DE) 1995-10-17 US disclosed
US-5194660-A Processes for producing carbamates and isocyanates UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1993-03-16 US disclosed
US-5169954-A Process for the N-alkylation of ureas CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) 1992-12-08 US disclosed
JP-H04270257-A N-ALKYLATION OF UREA COMPOUND CHEM LINZ AG 1992-09-25 JP disclosed
US-5124451-A PROCESS FOR THE N-ALKYLATION OR UREAS CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) 1992-06-23 US disclosed
EP-0083096-B1 PRODUCTION OF URETHANE COMPOUNDS Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1987-02-25 EP disclosed
US-4621149-A PLATINUM GROUP METAL HALOGEN OR HALOGEN COMPOUND ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1986-11-04 US disclosed
EP-0083096-A2 Production of urethane compounds Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1983-07-06 EP disclosed
US-4388245-A OF LOW VISCOSITY ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1983-06-14 US disclosed
US-3976622-A POLYURETHANES BAYER AKTIENGESELLSCHAFT (DT) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION ASNS, GLUL, GNMT EPHX1 4343/4885EPHX2 4433/4885MMP2 231/4885
US-20230322785-A1 ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY ADORA2A, ADORA2B, ADORA1 EPHX1 1759/4885EPHX2 564/4885MMP2 3870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.